Cetera Investment Advisers lowered its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) by 24.1% in the second quarter, Holdings Channel.com reports. The firm owned 10,718 shares of the pharmaceutical company’s stock after selling 3,396 shares during the period. Cetera Investment Advisers’ holdings in Vertex Pharmaceuticals were worth $3,020,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the stock. Cetera Advisor Networks LLC boosted its stake in Vertex Pharmaceuticals by 2.6% during the 2nd quarter. Cetera Advisor Networks LLC now owns 6,657 shares of the pharmaceutical company’s stock valued at $1,876,000 after purchasing an additional 170 shares during the last quarter. Checchi Capital Advisers LLC boosted its stake in Vertex Pharmaceuticals by 9.1% during the 2nd quarter. Checchi Capital Advisers LLC now owns 1,560 shares of the pharmaceutical company’s stock valued at $437,000 after purchasing an additional 130 shares during the last quarter. King Luther Capital Management Corp purchased a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth approximately $267,000. Bridgewater Associates LP boosted its stake in shares of Vertex Pharmaceuticals by 620.2% in the 2nd quarter. Bridgewater Associates LP now owns 217,152 shares of the pharmaceutical company’s stock worth $61,191,000 after buying an additional 187,000 shares during the last quarter. Finally, Apollon Wealth Management LLC boosted its stake in shares of Vertex Pharmaceuticals by 11.9% in the 2nd quarter. Apollon Wealth Management LLC now owns 3,353 shares of the pharmaceutical company’s stock worth $945,000 after buying an additional 357 shares during the last quarter. Institutional investors and hedge funds own 91.33% of the company’s stock.
Wall Street Analysts Forecast Growth
VRTX has been the topic of a number of research analyst reports. Barclays boosted their target price on Vertex Pharmaceuticals from $307.00 to $313.00 and gave the stock an “overweight” rating in a research note on Friday, October 28th. Cowen boosted their target price on Vertex Pharmaceuticals from $315.00 to $330.00 in a research note on Friday, October 28th. Piper Sandler boosted their target price on Vertex Pharmaceuticals from $288.00 to $293.00 in a research note on Sunday, October 16th. StockNews.com initiated coverage on Vertex Pharmaceuticals in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Finally, HC Wainwright boosted their target price on Vertex Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a research note on Friday, August 5th. Six investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $305.33.
Insider Buying and Selling at Vertex Pharmaceuticals
Vertex Pharmaceuticals Trading Down 1.7 %
Shares of VRTX stock opened at $316.16 on Thursday. The company’s fifty day simple moving average is $299.30 and its two-hundred day simple moving average is $285.26. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.70 and a quick ratio of 4.55. Vertex Pharmaceuticals Incorporated has a 1 year low of $182.66 and a 1 year high of $323.61. The stock has a market capitalization of $81.16 billion, a price-to-earnings ratio of 24.93, a PEG ratio of 1.81 and a beta of 0.44.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.
- Get a free copy of the StockNews.com research report on Vertex Pharmaceuticals (VRTX)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.